The global Dry Powder Inhaler (DPI) Devices Market is experiencing significant growth due to the increased prevalence of respiratory ailments such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis. In 2022, the market size was estimated to be USD 19.66 billion, and it is expected to reach USD 27.98 billion by 2032, with a compound annual growth rate (CAGR) of 4%.
Manufacturers are focusing on developing technologically advanced DPI devices to meet the demands of patients with respiratory disorders. DPIs are preferred by patients due to their convenience and ease of use. Unlike traditional inhalers, DPIs do not require propellants, making them environmentally friendly. Additionally, DPIs have the advantage of delivering dry powder medications directly to the lungs, enhancing their effectiveness in treating respiratory illnesses.
Government programs and funding for respiratory illness research are also contributing to the increased demand for DPI devices. Initiatives such as the National Heart, Lung, and Blood Institute in the United States, established by the National Institutes of Health (NIH), are supporting research on respiratory illnesses and driving the adoption of DPI devices in the region.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/download-free-sample/1233
Some major companies in the global dry powder inhaler device market include:
- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Chiesi Farmaceutici S.p.A.
- Cipla Inc.
- 3M Company
- Hovione
- DPI Co., Ltd.
The development of personalized medicine and innovative drug formulations is another factor driving the growth of the DPI device market. Manufacturers are working on DPI devices that can deliver a variety of dry powder pharmaceutical formulations, including combination treatments. This expanded functionality increases the usage of DPI devices in the treatment of respiratory disorders.
Technological advancements have led to the introduction of smart DPI devices. These devices incorporate sensors and provide real-time feedback on patient adherence and medicine consumption, leading to improved patient outcomes.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have established guidelines and safety regulations for the effectiveness, labeling, and use of dry powder inhalers. The FDA recognizes DPIs as a safe and efficient method of administering medications to individuals with respiratory conditions.
To mitigate the use of ozone-depleting compounds, the U.S. Environmental Protection Agency (EPA) has implemented regulations that restrict the use of chlorofluorocarbons (CFCs) or hydrochlorofluorocarbons (HCFCs) in all products, including DPI devices.
Overall, the global market for dry powder inhaler devices is driven by the increasing demand for respiratory ailment treatments, advancements in technology, and government support for respiratory illness research. The market is expected to continue growing as manufacturers focus on developing more advanced and user-friendly DPI devices.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.reportsanddata.com/report-detail/dry-powder-inhaler-device-market
Some key highlights from the report include:
- In 2021, the multi-dose sector held a larger market revenue share compared to other types of inhaler devices. Multi-dose inhalers are preferred by patients due to their affordability, ease of use, and the convenience of delivering multiple doses from a single inhaler. They ensure consistent and effective medication administration, making them suitable for respiratory conditions like asthma and COPD.
- The COPD segment accounted for the largest revenue share in the inhaler device market in 2021. The increasing prevalence of COPD globally, driven by factors like an aging population and smoking, contributes to the growth of this segment. Dry powder inhaler devices are considered highly effective for COPD treatment, providing quick relief and ease of use.
- The North American region is expected to dominate the DPI device market, holding the largest market share. Factors such as an aging population, increasing respiratory conditions, preference for portable and user-friendly devices, and government initiatives for respiratory health contribute to market expansion in this region.
- Prominent players in the global dry powder inhaler device market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Chiesi Farmaceutici S.p.A., Cipla Inc., 3M Company, Hovione, and DPI Co., Ltd.
- GlaxoSmithKline plc collaborated with Innoviva, Inc. in 2020 to develop and market respiratory medication, including dry powder inhaler devices, to enhance their market presence and research innovative medicines for respiratory disorders.
- AstraZeneca plc acquired Pearl medicines Inc. in 2020, aiming to expand its respiratory portfolio and strengthen its position in the dry powder inhaler device market.
- GlaxoSmithKline plc introduced the Ellipta® inhaler device in 2020, designed for the administration of respiratory medications, including dry powder formulations. The device's simplicity and functionality make it suitable for individuals with respiratory disorders.
- Boehringer Ingelheim International GmbH launched the Respimat® inhaler device in 2020, delivering their respiratory medicine portfolio, including dry powder formulations. The device utilizes a unique inhalation mechanism, providing a mist of medicine to the lungs for quick and effective relief.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.reportsanddata.com/request-customization-form/1233
For the purpose of this report, Reports and Data has segmented the global dry powder inhaler device market on the basis of Type Outlook, Application Outlook, and Regional Outlook:
Type Outlook (Revenue, USD Billion; 2022 - 2032)
- Single-dose
- Multi-dose
Application Outlook (Revenue, USD Billion; 2022 - 2032)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Others
Regional Outlook (Revenue, USD Billion; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Latest Research Reports Published by Reports and Data:
Viral Molecular Diagnostics Market, By Technique (Polymerase chain reaction, Real time PCR), By Product (Instruments, Reagents, Others), By Application, (AIDS, Hepatitis), By End-Use, and By Region Forecast to 2030
Hematological Cancers Therapeutics Market, By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Stem Cell Transplantation), By Indication (Leukemia, Lymphoma, and Multiple Myeloma), and By Region Forecast to 2032
Dry Powder Inhaler Device Market, By Type (Single-Dose and Multi-Dose), By Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Others), and By Region Forecast to 2032
Enteral Feeding Formulas Market, By Product Type (Standard Formula, Disease-Specific Formula, and Blenderized Formula), By Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), and By Region Forecast to 2032
Positron Emission Tomography Market Size, Share and Trends Analysis Report By Type (Full-Ring PET Scanners, Partial Ring PET Scanners), By Application, By End-user, By Region, Competitive Strategies and Segment Forecasts to 2016-2026
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Read our Press Release @ https://www.reportsanddata.com/press-release/global-dry-powder-inhaler-device-market
Trending Titles Compression Therapy Market | Orthopedic Biomaterials Market